Establishment of clonal myogenic cell lines from severely affected dystrophic muscles - CDK4 maintains the myogenic population by Stadler, Guido et al.
RESEARCH Open Access
Establishment of clonal myogenic cell lines from
severely affected dystrophic muscles - CDK4
maintains the myogenic population
Guido Stadler
1, Jennifer CJ Chen
2, Kathryn Wagner
3, Jerome D Robin
1, Jerry W Shay
1, Charles P Emerson Jr Jr
2,
Woodring E Wright
1*
Abstract
Background: A hallmark of muscular dystrophies is the replacement of muscle by connective tissue. Muscle
biopsies from patients severely affected with facioscapulohumeral muscular dystrophy (FSHD) may contain few
myogenic cells. Because the chromosomal contraction at 4q35 linked to FSHD is thought to cause a defect within
myogenic cells, it is important to study this particular cell type, rather than the fibroblasts and adipocytes of the
endomysial fibrosis, to understand the mechanism leading to myopathy.
Results: We present a protocol to establish clonal myogenic cell lines from even severely dystrophic muscle that
has been replaced mostly by fat, using overexpression of CDK4 and the catalytic component of telomerase (human
telomerase reverse transcriptase; hTERT), and a subsequent cloning step. hTERT is necessary to compensate for
telomere loss during in vitro cultivation, while CDK4 prevents a telomere-independent growth arrest affecting CD56
+ myogenic cells, but not their CD56- counterpart, in vitro.
Conclusions: These immortal cell lines are valuable tools to reproducibly study the effect of the FSHD mutation
within myoblasts isolated from muscles that have been severely affected by the disease, without the confounding
influence of variable amounts of contaminating connective-tissue cells.
Background
Most muscular dystrophies result from a defect within
myogenic cells that leads to progressive muscle weak-
ness and wasting, and in severe cases, to the replace-
ment of muscle fibers by connective tissue and/or fat.
At advanced stages, skeletal muscle is replaced by
fibroblasts and adipocytes. Although these cell types
probably promote disease in later stages, it is generally
believed that the root cause leading to most muscular
d y s t r o p h i e si sad e f e c to r i g inating in myogenic cells.
We therefore developed a protocol to enrich, immorta-
l i z ea n di s o l a t er a r em u s c l ep r o g e n i t o rc e l l sf r o m
severely affected dystrophic muscles to obtain clonal
myogenic cell lines. In this report, the protocol is
described for cells isolated from skeletal muscle of
people with facioscapulohumeral muscular dystrophy
(FSHD), but the technique is also applicable to other
muscular dystrophies.
FSHD has been linked to deletions of D4Z4 tandem
repeats at chromosome 4q [1], but it is still unclear how
this deletion causes disease. Primary skeletal-muscle cul-
tures have been used in attempts to model the disease,
and several FSHD-specific phenotypes, such as increased
vacuolization and sensitivity to oxidative stress [2] have
been described. In addition, there have been reports
describing incorrect expression of various FSHD candi-
date genes in muscles and myogenic cells from patients
with FSHD, including FSHD region gene (FRG)1 and
the double homeobox (DUX)4 gene [3-6]. However, in
many instances, these findings have not been consistent
between different laboratories, perhaps as a result of
variables such as muscle type, disease progression, cul-
ture purity, in vitro culture conditions or replicative age
of the cells. In particular, because of their low replicative
potential, it is difficult to use the same purified primary
cultures for multiple large-scale experiments in different
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material. Immortal cell lines provide a solution to this
problem, and are a useful and unlimited resource for
the research community.
To immortalize FSHD muscle-derived myogenic
cells, we used the same strategy as previously
described for normal skeletal-muscle cells; that is,
ectopic expression of human telomerase reverse tran-
scriptase (hTERT) to overcome replicative senescence,
and of CDK4 to block the growth arrest due to cell-
culture stress (stress or aberrant signaling-induced
senescence (stasis)) [7]. Replicative senescence is an
irreversible growth arrest triggered by a DNA damage
signal from critically short telomeres [8,9]. Telomere
shortening occurs during each cell division, because of
the end replication problem [10], end processing [11]
and oxidative damage [12], and can be prevented by
addition of telomeric repeats by the reverse transcrip-
tase telomerase [13,14]. Overexpression of hTERT, the
catalytic subunit of telomerase, has been shown to
prevent senescence of a variety of human somatic
cells that do not express this gene endogenously
[15-17]. However, inadequate in vitro culture condi-
tions can cause accumulating stress to certain cell
types, which may lead to stasis, a premature growth
arrest independent of telomere length. We have
shown that overexpression of CDK4 is able to bypass
stasis in many cell types, including myoblasts, while
maintaining normal phenotypes and cell cycle control
[7,18]. We show in this paper that overexpression of
CDK4 delays or even prevents overgrowth of myo-
genic CD56+ cells by their non-myogenic CD56-
counterparts, and therefore facilitates the isolation of
clonal myogenic cell lines from severely affected dys-
trophic muscles.
Results
Primary cultures from severely affected FSHD muscles
primarily consist of non-myogenic cells
During progression of FSHD, the muscle fibers of cer-
tain skeletal muscles are progressively replaced by con-
nective tissue. The biceps is one of the muscles
preferentially affected by FSHD (Figure 1A). Despite
good strength in the biopsied biceps, muscle fibers from
the biceps of a 42-year-old man with FSHD (subject
01A) were found to be in close association with fibrotic
tissue and surrounded by large pockets of adipose cells.
By contrast, the biceps muscle from his 46-year-old
healthy brother (subject 01U, inset) exhibited no endo-
mysial fibrosis, and was virtually free of adipocytes. The
percentage of myogenic cells in the primary cell cultures
from the biceps muscle of 01A (designated 01Abic) was
only 20%, and decreased rapidly during in vitro cultiva-
tion (Figure 1B). We used CD56 to identify myogenic
cells and validated this by several observations. First,
CD56+ and CD56- cells were distinct and stable popula-
tions (Figure 1C), and skeletal-muscle cells did not
switch between a CD56+ and CD56- phenotype. Second,
CD56+, but not CD56- cells, expressed the intermediate
filament protein, desmin, another marker of skeletal-
muscle cells (Figure 1D). Third, purified CD56+ but not
CD56- populations fused into multinucleated myotubes
when changed to differentiation medium (Figure 1E).
CDK4 maintains the myogenic population
To test the hypothesis that stasis of CD56+ cells is
responsible for their overgrowth by CD56- cells in vitro,
we infected primary 01Abic cells with a retrovirus con-
taining CDK4 at the fifth population doubling (PD5),
when the fraction of CD56+ cells was about 20%.
Whereas the percentage of CD56+ cells quickly dropped
towards zero in uninfected cells (Figure 2A, blue line
with yellow circles), CDK4 overexpression maintained
the CD56+ cells at roughly 20% for an additional 50
days, corresponding to about 25 PDs (Figure 2A, blue
line with blue squares). The effect of CDK4 on mainte-
nance of the CD56+ population was also dramatic in
the primary cells cultured from the 01U biceps (desig-
nated 01Ubic) (Figure 2A, red lines). At early PDs, this
cell strain consisted of a seemingly pure myogenic popu-
lation, which nonetheless was overgrown by initially rare
CD56- cells (Figure 2A, red line with yellow circles) at
between 30 and 50 days of culture. CDK4 overexpres-
sion prevented this overgrowth, and maintained the
CD56+ population for the entire culture period (Figure
2A, red line with red squares). These experiments sug-
gest that CDK4 overexpression confers a selective
growth advantage on CD56+ cells compared with their
CD56- counterparts. This hypothesis was confirmed by
infection of CD56 sorted 01Abic cells with CDK4
(Figure 2B). Overexpression of CDK4 led to a doubling
of the replicative lifespan of CD56+ cells, from about 40
to 80 PDs. In the absence of CDK4, the growth rate of
the CD56+ cells began to slow down as early as PD20,
contributing to the overgrowth by CD56- cells long
before the CD56+ cells actually had their growth
arrested. By contrast, CDK4 had only a minor effect on
the lifespan of CD56- cells. Telomeres of CD56- cells
were shorter than those of their CD56+ counterparts at
growth arrest in the absence of CDK4, consistent with
the interpretation that CD56- cells arrested because of
replicative aging, whereas CD56+ cells arrested because
of stasis before reaching the telomere-based replicative
limits. CDK4 overexpression led to further telomere
shortening during the increased lifespan of the CD56+
population, reaching lengths similar to those of the
senescent CD56- population when they finally became
senescent (not shown).
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Page 2 of 10Figure 1 Replacement of FSHD muscle by non-myogenic cells. (A) Transverse section of the biceps muscle from subject 01A with
facioscapulohumeral muscular dystrophy (FSHD), showing extensive fibrosis and large pockets of adipocytes; muscle fibers displayed variable
diameter. By contrast, biceps muscle from his brother (subject 01U, inset) had a relatively uniform array of myogenic fibers with no endomysial
fibrosis or fatty infiltration. Hematoxylin and eosin, original magnification 20 ×. (B) Percentage of CD56+ cells in primary cell cultures isolated
from FSHD biceps muscle shown in (A) during in vitro cultivation. PD = population doubling. (C) Growth curves of sorted CD56+ (red squares)
and CD56- (green squares) populations from the primary 01A biceps cell culture. The percentage of CD56+ cells in sorted, CD56+ and CD56-
cultures over time are also displayed (circles outlined in red (CD56+) or green (CD56-)). (D) Desmin immunostaining (green) of sorted CD56+
and CD56- cells. Nuclei were counterstained with 4’,6-diamidino-2-phenylindole (blue). (E) Sorted CD56+ and CD56- cells after 3 days in
differentiation medium.
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isolated after immortalization of primary cultures
consisting mainly of CD56- cells
Even though pure myogenic populations can be isolated
from mixed primary cultures using antibody based
methods, such as fluorescence or magnetic-activated cell
s o r t i n g( F A C So rM A C S ) ,t h o s ec e l l sh a v eav e r y
restricted replicative lifespan, and therefore can be used
for only a limited number of experiments. We thus
established the following protocol to isolate immortal
clonal myogenic cell lines from severely affected dys-
trophic muscle. Primary cultures (in this case, 01Abic,
containing only 20% CD56+ cells) were consecutively
infected with retroviruses for overexpression of CDK4
and hTERT, and then uniformly CD56-expressing
clones were isolated (Figure 3A). In our hands, differ-
ences in viral titers, multiplicity of infection (MOI) and
virus type have not had significant effects on rate of
immortalization, and we have obtained similar results
using low MOI retroviruses or high MOI lentiviruses.
For the experiments published here, about 1% of the
cells survived selection and therefore had been trans-
duced, corresponding to an MOI of ~0.01. As CDK4
expression maintains the myogenic population, the
immortal population had an increased and stable per-
centage of CD56+ cells after drug selection compared
with the parental population at the same time point
(14% vs. 2%), and no sorting step before infection was
necessary to isolate myogenic clones, which could be
carried out easily and with little effort. Healthy-looking
and well-separated clones were picked, roughly 90% of
which survived the subsequent expansion to the ~2 ×
10
6 cells necessary for cryopreservation and analysis for
myogenicity (CD56 expression and fusion competence).
Of 15 randomly analyzed clones, four (27%) were myo-
genic. The higher percentage of myogenic clones than
CD56+ cells in the immortal population (27% vs. 14%)
is consistent with the observed growth advantage for
CD56+ over CD56- cells at clonal density (data not
shown). Growth curves of three immortal myogenic
clones are shown in Figure 3C, in comparison with the
CD56 sorted primary culture, with and without CDK4.
Immortalized myoblasts had a doubling time of about
24 to 30 hours, which we found was only slightly higher
than that of primary cultures at early PDs (~20 to 26
hours). All clones underwent >200 PDs without any sign
of growth retardation. Whereas telomere restriction
fragment analysis showed that telomeres were extended
by ectopic hTERT for most myoblast clones (Figure 3B,
immortal clone number 6 as a representative example),
some clones maintained telomere lengths at levels simi-
lar to that of the primary culture (Figure 3B, compare
immortal clone number 2 with the primary CD56+
population). The different telomere dynamics may be
due to a variety of factors, including hTERT integration
site-specific hTERT transcription, or differences in fac-
tors affecting telomerase enzyme assembly, recruitment
or activity at telomeres.
All immortal clones stably expressed CD56 and des-
min, and retained their ability to fuse into myosin-
expressing, multinucleated myotubes when moved to
differentiation medium (Figure 4, 01Abic immortal
Figure 2 CDK4 maintains the myogenic population. (A) Percentage of CD56+ cells in primary cultures from biceps muscle of a subject with
facioscapulohumeral muscular dystrophy (FSHD) (01Abic) and his unaffected brother (01Ubic) with and without overexpression of CDK4. (B)
Growth curves of CD56 sorted 01Abic cells with and without overexpression of CDK4.
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however, the differentiation kinetics were found to slow
down with time in culture. Immortal clones at early PDs
(Figure 4, PD35) readily formed very large myotubes
after only 3 days in differentiation medium; ~70% of
nuclei were present in multinucleated and/or myosin-
positive cells, detected by immunostaining with MF20
antibody. By contrast, after >100 PDs (Figure 4, PD120
and PD234), fusion was delayed and resulting myotubes
were thinner, with <10% of nuclei present in MF20-
positive cells on day 3, and approximately 50% (PD120)
and 30% (PD234) appearing in multinucleated/MF20-
positive cells at day 7.
Discussion
Since the description of the first cancer cell line [19],
infinitely growing human cell lines have been invaluable
tools in biology. In contrast to most cancer cells that
are immortal, human somatic cells have a finite lifespan
and have to be ‘immortalized’ to obtain unlimited prolif-
erative capacity. Historically, this was initially achieved
by overexpression of viral oncogenes such as simian
v i r u s( S V ) 4 0[ 2 0 ] ,w h i c hi sa l w a y sa s s o c i a t e dw i t ha t
least some degree of neoplastic transformation. By con-
trast, hTERT overexpression not only immortalizes a
variety of human primary cultures, but has been
reported to do this while also maintaining the cellular
Figure 3 Isolation of immortal CD56+ clones. (A) FACS histograms of primary 01Abic cells at PD7 (left) and two clones at PD35, one CD56+
and the other CD56-, after immortalization with CDK4 and human telomerase reverse transcriptase (hTERT) (right). Red lines represent cells
treated with anti-CD56 antibody; green lines represent controls where the primary antibody was omitted, and hence they correspond to
nonspecific background fluorescence. The percentage of CD56+ cells (fluorescence greater than background) is indicated. (B) Telomere
restriction fragment analysis gel showing telomere length dynamics of the CD56+ population and two immortalized CD56+ clones at different
PDs. (C) Growth curves of primary 01Abic cells sorted for CD56 (CD56+ population, red squares), cells infected with CDK4 (CD56+ population
CDK4, red diamonds) and three CD56+ immortalized clones (blue lines).
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been challenged by the observation of putative non-telo-
meric activities of hTERT [23-25], with strong evidence
for its potential to modulate the Wnt pathway in mice
[26]. In most myoblast clones, expression of hTERT for
just a few PDs is sufficient to elongate telomeres by sev-
eral kilobases (Figure 3C, clone number 6). Although
the importance of the Wnt pathway in skeletal-muscle
differentiation is well documented [27], we have not
found any obvious phenotypic change between the
hTERT-expressing cells described here and cell models
that only transiently overexpress hTERT before Cre
recombinase-mediated excision of the hTERT cassette
(Stadler and Wright, unpublished data). The slower dif-
ferentiation kinetics and formation of thinner myotubes
seen in high passage hTERT cells (Figure 4) were not
due to a direct effect of ectopic hTERT, as this pheno-
type was not seen with lower passage cells, in which
hTERT had already been expressed for >20 PDs. We
suggest that this change in differentiation kinetics is
instead due to prolonged in vitro cultivation and its
associated potential for epigenetic drift and constant
selection for proliferation. Hence, it is crucial to take
the replicative history of a cell into account, even for
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Figure 4 Characterization of an immortal CD56+ clone during in vitro propagation. Three time points are shown: population doubling
(PD) 35, 120 and 234 (see growth curve in Figure 3C). Top row: flow cytometry histograms of CD56 stained cells (red lines) and control cells
without the primary antibody (green lines, representing background fluorescence). Uniform expression of CD56 was maintained throughout
>200 PDs of in vitro cultivation (percentage of CD56+ cells is indicated). Second row: cells stained for expression of the muscle-specific
intermediate-filament protein, desmin (green) and counterstained with 4’,6-diamidino-2-phenylindole (DAPI) (blue). Third and fourth rows: phase
(third row) and fluorescence (fourth row) images of cells in differentiation medium after 3 days (PD 35) or 7 days (PD 120 and PD234) and
stained for myosin heavy chain (MF20, green) and DNA (DAPI, blue).
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on cell lines at roughly similar PD levels. In situations
where this is not practical, it may be necessary to con-
firm that myogenic potential and differentiation kinetics
have not changed with additional culturing. These are
also important variables to consider when comparing
different cell lines and cell clones with one another.
Although there may be insertion-specific variation, our
findings link changes in the differentiation ability of a
cell line with the time spent by that cell line in culture.
The conditions for immortalization of human myo-
blasts were initially established using primary cultures
from the pectoralis major mu s c l e[ 7 ] .I na d d i t i o nt o
cell-culture supplements, such as dexamethasone and
hepatocyte growth factor, ectopic CDK4 was necessary
to prevent telomere-independent growth arrest (stasis).
Fetal lung fibroblasts require the spin-trap compound n-
tert-butyl hydroxylamine in addition to low oxygen to
avoid stasis [28], but this substance was extremely toxic
to myoblasts (unpublished observations). This might
reflect the consequences of blocking nitric oxide signal-
ing in myoblasts [29].
In fetal fibroblasts and epithelial cells, stasis is often
associated with an increase in p16 [18,28], and therefore
ectopic expression of CDK4 was chosen to titer out the
upregulation of this cell cycle inhibitor. Whereas others
have shown that p16 is increased in growth-arresting
myoblasts [30], we found that p16 levels are not
increased in human myoblasts during stasis [7]. Differ-
ential regulation of cell cycle inhibitors in vitro may be
explained by different culture conditions, or by develop-
mental differences of fetal versus adult myoblasts (used
in the former and latter studies, respectively), as has
been shown for fibroblasts [28]. We are currently inves-
tigating which factors prevent adult myoblasts from
being immortalized by hTERT in the absence of CDK4
and are hence responsible for stasis.
In contrast to CD56+ myoblasts, CD56- cells did not
exhibit stasis under our culture conditions, which were
originally optimized for myoblasts. This is supported by
the following observations: First, CDK4 overexpression
in CD56- cells did not lead to a significant increase in
their proliferative potential. Second, CD56- cells could
be immortalized by hTERT alone in conditions of low
oxygen (data not shown), suggesting that CD56+ cells
are more vulnerable to ‘stress’ (which triggers stasis)
compared with CD56- cells, and therefore CD56- cells
may have a growth advantage in ‘stressful’ situations,
such as during pathological regeneration of muscle in
vivo. Additionally, it seems that at low passage, sorted
CD56+ cells have growth rates similar to those of
CD56-, whereas the former are rapidly overgrown when
unsorted, arguing that CD56- cells might inhibit growth
of CD56+ cells. One candidate for this inhibitory activity
is myostatin, which has been shown to be expressed by
both skeletal-muscle fibroblasts and myoblasts [31], and
to inhibit proliferation of myoblasts [32]. Our immorta-
lized CD56+ and CD56- clones from skeletal muscle
provide a model system to study the relationship
between them and to help elucidate the intercellular
crosstalk and regulatory pathways between different cell
types.
Although we cannot exclude the possibility that pri-
mary cultures from skeletal muscle contain non-myo-
genic CD56+ cells, such as infiltrating immune cells
[33], all CD56+ immortal clones analyzed to date in our
laboratory (>20) were desmin-positive and fusion-
competent.
Conclusions
In summary, we describe a simple and efficient protocol
to establish immortal myogenic cell lines from dys-
t r o p h i cm u s c l et h a tc o n s i s t sm a i n l yo fn o n - m u s c l et i s -
sue. Additionally, we provide evidence that stasis of
myoblasts and not their CD56- counterpart is responsi-
ble for overgrowth of the former by the latter in primary
cultures, which can be prevented by ectopic CDK4. To
our knowledge, this is the first report of immortal myo-
genic human cell lines harboring the FSHD mutation,
and will be useful in investigating this enigmatic disease.
Methods
The study was approved by The Johns Hopkins Medi-
cine Institutional Review Board.
Human subjects and tissue collection
T h em a l ep r o b a n d( s u b j e c t0 1 A )f i r s te x h i b i t e dw e a k -
ness in the legs as a teenager. At time of enrollment, he
was 42 years old, and exhibited mild facial weakness,
scapular winging and asymmetric weakness in the limbs,
consistent with the FSHD phenotype. Molecular diagno-
sis of FSHD was confirmed by the University of Iowa
Diagnostic Laboratories, which identified a HindIII 4qA
allele of 26 kb in length. An open muscle biopsy was
taken from the biceps muscle (01Abic), which had its
strength rated as 4+ out of 5 on the modified Medical
Research Council scale. Tissue was also obtained from
the biceps muscle (01Ubic) of the proband’s 46-year-old
brother (01U), who had full muscle strength and no dis-
ease allele found on gene testing. Approximately 300 mg
of tissue was reserved for histological and biochemical
assays, and ~500 to 700 mg tissue was used for primary
cell isolation.
Primary cell isolation and cell culture
The biceps muscle tissue was minced into fragments of
<5 mm
2, and stored at 4°C in a Ham’s F10 medium con-
taining 20% fetal bovine serum (FBS; Hyclone, Thermo
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and 2.5 ng/ml basic fibroblast growth factor (Biopioneer,
San Diego, CA, USA), supplemented with 1% antibiotic/
antimycotic (Cellgro, Manassas, VA, USA) until pro-
cessed for cell isolation (within approximately 24 hours
of biopsy) (viable cells have been successfully isolated
from tissues stored in this manner up to 6 days after
biopsy). Tissue was cleaned and minced in Hanks’
balanced salt solution (HBSS, catalogue number 14175;
Gibco, Grand Island, NY, USA) and dissociated in 5 ml
of enzyme solution (1 mg/ml collagenase IV, 2.4 U/ml
dispase (both Worthington, Lakewood, NJ, USA) and
2.5 mmol/l CaCl2 in HBSS] for 45 minutes at 37°C, tri-
turating every 15 minutes with a 5 ml serological pipette
(moving it up and down ~10 to 15 times), and filtered
through 100 μma n d4 0μm cell sieves (BD Biosciences,
Bedford, MA, USA). Cells were pelleted by spinning in a
centrifuge at 1000 g for 5 minutes, and resuspended in
2m lg r o w t hm e d i u m( H a m ’s F-10 supplemented with
20% FBS (Hyclone), 0.5% chick embryo extract, 1.2
mmol/l CaCl2 and 1% antibiotic/antimycotic (Cellgro),
prepared as fresh stock at least every 7 days) and
counted with a hemocytometer. The 01Abic cells were
seeded in 2 ml growth medium on a 35 mm gelatin-
coated dish, and the 01Ubic cells were seeded on a 60
mm dish in 5 ml growth medium. Cells were cultured
undisturbed for 48 hours, after which they were given
fresh growth medium daily for 2 to 4 days. When
approximately 50 to 70% confluent, cells were treated
with trypsin (TrypLE Express/Gibco) for 5 minutes at
37°C, neutralized with an equal volume of growth med-
ium, and counted with a hemocytometer. For expansion,
cells were seeded at ~2000 to 3000 cells/cm
2 in growth
medium. For freezing, an equal volume of ice-cold 2 ×
freezing medium (20% dimethysulfoxide, 50% FBS, 30%
growth medium) was added to cells and mixed well,
then cells were incubated in the liquid nitrogen vapor
phase for at least 1 hour before storage at -140°C.
To standardize conditions for growth of primary and
immortalized cells, primary myoblasts were subsequently
cultured in a 4:1 mixture of Dulbecco modified Eagle
medium (DMEM) and Medium 199 (Hyclone), supple-
mented with 15% FBS (Hyclone), 0.02 M HEPES buffer,
1.4 mg/l vitamin B12 (both Sigma-Aldrich, St. Louis,
MO, USA), 0.03 mg/l ZnSO4 (Fisher Scientific, Fair
L a w n ,N J ,U S A ) ,0 . 0 5 5m g / ld e x a m e t h a s o n e( S i g m a -
Aldrich), 2.5 μg/l hepatocyte growth factor (Chemicon
International, Temecula, CA, USA) and 10 μg/l basic
fibroblast growth factor (BioPioneer), on dishes coated
with 0.1% pigskin gelatin (Sigma-Aldrich) in a 2-5% oxy-
gen environment [34]. Hepatocyte and fibroblast growth
factors were added to a volume of medium that was
used within 1 week. Cells were routinely grown in 100
mm tissue culture dishes (BD Falcon, Franklin Lakes,
NJ, USA) covered by 10 ml medium, with a weekly
medium change if cells were not passaged before that
(usually one passage every 5 to 7 days). Cells were pas-
saged at 50 to 90% confluency using 0.05% trypsin/
EDTA (Gibco), and cell numbers determined (Z1 Coul-
ter Particle Counter; Beckman Coulter, Miami, FL,
USA). PD was calculated using the formula: PD = ln
[(final number of cells)/(initial number of cells)]/In(2).
For differentiation, 1.2 × 10
5 myoblasts were seeded in
six-well dishes, then 24 hours later, cells were washed
twice with phosphate-buffered saline (PBS) and fed with
differentiation medium (DMEM and Medium 199 in a
ratio of 4:1, supplemented either with 2% horse serum
(Gibco) or with 0.02 mol/l HEPES plus 10 mg/l insulin
and 100 mg/l apo-transferrin (both Sigma-Aldrich)).
Results obtained were similar with both differentiation
media, although a delay of ~1 day was observed with
horse serum relative to insulin/transferrin.
Retroviral infection
The construction of the vectors used for immortaliza-
tion (CDK4-pBabe-neo and hTERT-pBabe-Hygro), has
been described previously [7,18]. In brief, mouse CDK4
(kindly provided by Charles J. Sherr) and hTERT
cDNAs were inserted into pBabe vectors [35] containing
neomycin- and hygromycin-resistance genes, respec-
tively. Additionally, loxP sites were placed internal to
the long terminal repeats of the hTERT expression vec-
tor, to allow for excision of the entire expression cas-
sette by Cre recombinase. These vectors were
transfected into the Phoenix ecotropic packaging cell
line using the calcium phosphate technique [36], and
the virus-containing supernatant was used to infect the
amphotropic packaging cell line PA317 [37] to obtain
stable virus-producing cell lines after selection with 0.5
mg/ml G418 or hygromycin (EMD Biosciences, San
Diego, CA, USA). All infections were performed in the
presence of 2 μg/ml polybrene (Sigma-Aldrich).
For infection of myoblasts, 5 × 10
4 cells were seeded
in six-well dishes 24 hours before infection. Selection
was started 48 hours after infection using 300 mg/l
hygromycin and 400 mg/l G418 for 1 and 2 weeks,
respectively. Depending on growth rates and infection
efficiency, cells were passaged during the selection per-
iod before becoming confluent.
Isolation of myogenic immortalized clones
Immortalized populations were seeded at low densities,
(50, 100, 200 or 400 cells per 100 mm dish). About 10
days after seeding, clones were isolated using cloning
rings and seeded into 48-well dishes, followed by six
well and 100 mm dishes. The exact time point for clone
isolation was chosen to maximize the cell number and
minimize cell density of individual clones, to facilitate
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respectively. We estimate that clones contained 100 to
1000 cells at the time of isolation. All clones were ana-
lyzed for CD56 expression by flow cytometry (see
below) and fusion potential in differentiation medium.
The percentage of cell nuclei in multinucleated and/or
MF20-positive cells was determined for 10 random
fields after 3 or 7 days in differentiation medium.
Terminal restriction fragment assay
Terminal restriction fragment assay was performed as
previously described [38].
Flow cytometry
Cells were detached with trypsin, counted, and sedimen-
ted by centrifugation, then 1.5 × 10
5 cells were resus-
pended in 0.2 ml DMEM with 10% calf serum (Cosmic
Calf Serum; Hyclone) containing 5% supernatant from
the hybridoma line 5.1H11 [39], which recognizes CD56
(kindly provided by Helen Blau). As a control, primary
antibody was omitted. Cells were incubated for 30 min at
room temperature, washed twice with 10% calf serum
(Cosmic Calf Serum; Hyclone) in PBS, and incubated
with secondary Alexa488-conjugated goat anti-mouse
antibody (Invitrogen, Eugene, OR, USA) for 30 min at
room temperature. After washing with PBS, cells were
resuspended in 0.2 ml PBS and analyzed on a flow cyt-
ometer (FACSCalibur; Becton Dickinson). A second flow
cytometer (FACSAria; Becton Dickinson) was used for
sorting, with 5 × 10
6 cells stained in upscaled volumes.
Immunofluorescence
Cells on gelatin-coated glass chamber slides (Thermo
Scientific) were fixed with cold (-20°C) ethanol for 5
minutes, air-dried, and rehydrated with PBS. After
blocking with 10% calf serum (Cosmic Calf Serum;
Hyclone) in PBS, slides were incubated with primary
antibody (1:100 monoclonal mouse anti-desmin clone
D33 (Thermo Scientific, Rochester, NY, USA) or MF20
supernatant (myosin heavy chain, 1:30; Developmental
Studies Hybridoma Bank, Iowa City, IA, USA) for 1
hour at room temperature. Slides were washed three
times with PBS for 5 min, each and incubated with sec-
ondary Alexa488-conjugated goat anti-mouse antibody
(Invitrogen) for 1 hour at room temperature. After three
washes with PBS, slides were covered with mounting
medium containing 4’,6-diamidino-2-phenylindole (Vec-
tashield; Vector Laboratories, Burlingame, CA, USA)
and imaged with a fluorescence microscope (Axiovert
200 M; Zeiss).
Histology
Tissues were frozen in liquid nitrogen-cooled isopen-
tane, and cut on a cryostat. Frozen sections (0.8 μm)
were collected on microscope slides (Fisherbrand Super-
frost Plus; Fisher Scientific), air-dried, and fixed with 4%
formaldehyde in PBS for 15 minutes at room tempera-
ture. Slides were washed three times with PBS and
stained with hematoxylin and eosin. Sections were
imaged under a microscope (AxioImager M2, Zeiss) and
images captured with a camera (Digital microscopy
camera Axio Cam, ICC3, Zeiss).
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